Consensi is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Burke Therapeutics, Llc. The primary component is Amlodipine Besylate; Celecoxib.
| Product ID | 69101-505_99e8566d-75ed-391f-e053-2995a90af8f2 |
| NDC | 69101-505 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Consensi |
| Generic Name | Amlodipine Besylate And Celecoxib |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2019-12-17 |
| Marketing Category | NDA / NDA |
| Application Number | NDA210045 |
| Labeler Name | Burke Therapeutics, LLC |
| Substance Name | AMLODIPINE BESYLATE; CELECOXIB |
| Active Ingredient Strength | 5 mg/1; mg/1 |
| Pharm Classes | Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [CS],Cyclooxygenase Inhibitors [MoA],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2019-12-17 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA210045 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-12-17 |
| Marketing Category | NDA |
| Application Number | NDA210045 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2019-12-17 |
| Ingredient | Strength |
|---|---|
| AMLODIPINE BESYLATE | 5 mg/1 |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 69101-502 | Consensi | amlodipine besylate and celecoxib |
| 69101-505 | Consensi | amlodipine besylate and celecoxib |
| 69101-510 | Consensi | amlodipine besylate and celecoxib |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() CONSENSI 87295108 not registered Live/Pending |
Kitov Pharmaceuticals Ltd. 2017-01-10 |